Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Immuno-oncology firm Tioma Therapeutics closes $86mm Series A round

Executive Summary

Tioma Therapeutics Inc. (developing immunotherapies for solid tumors and blood cancers) raised $86mm through its Series A venture round. RiverVest Venture Partners, Novo Ventures, Roche Venture Fund, and SR One all co-led, and each take seats on the company's board. (Dr. John KcKearn of RiverVest will serve as chairman.)
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies